Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALG-125755
- Development stage
- Phase 1
- Lead developer
- Aligos Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ALG-125755 is a GalNAc-conjugated small interfering RNA (siRNA) developed by Aligos Therapeutics for the treatment of chronic hepatitis B. It specifically targets and inhibits the expression of hepatitis B surface antigen (HBsAg) by binding to argonaute-2 (AGO-2), which mediates RNA interference and leads to cleavage of HBV RNA in hepatocytes. Preclinical studies have demonstrated potent inhibition of HBsAg secretion with favorable safety and pharmacokinetic profiles, including a long liver half-life that may allow for less frequent dosing compared to other siRNAs. The drug is being investigated as part of efforts toward achieving a functional cure for chronic hepatitis B[1][2][5][6][7][8].
02
Targets
AGO2 (Argonaute RISC catalytic component 2)Hepatitis B virus small surface antigen messenger RNA
Beyond the preview
Go deeper on ALG-125755.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALG-125755.